Physician profile
David M Brown
NPI 1992800452
$1,038.26
in general payments reported to CMS, 2019-2025
21 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.71 · 2020: $140 · 2021: $47.40 · 2022: $310 · 2023: $254 · 2024: $88.27 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.80 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $208.97 | 2022-2025 | Ultomiris |
| Medtronic, INC. | $146.24 | 2022 | |
| Silk Road Medical, INC. | $107.15 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Biogen, INC. | $68.09 | 2020-2023 | Vumerity, Tysabri |
| Takeda Pharmaceuticals U.S.A., INC. | $64.84 | 2020-2021 | |
| Stryker Corporation | $53.49 | 2019 | |
| Eisai INC. | $46.27 | 2022 | |
| Microtransponder, INC. | $37.25 | 2023-2025 | |
| Argenx US, INC. | $36.08 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $32.18 | 2020 | |
| Medtronic USA, INC. | $32.10 | 2020 | |
| Ucb, INC. | $30.00 | 2025 | Rystiggo |
| Boston Scientific Corporation | $27.22 | 2019 | |
| Merz Pharmaceuticals, LLC | $26.08 | 2024 | Xeomin |
| Catalyst Pharmaceuticals, INC. | $24.44 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $24.02 | 2023 | Qutenza |
| Tanabe Pharma America, INC. | $23.49 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.18 | 2023 | Amvuttra |
| Axsome Therapeutics, INC. | $17.55 | 2025 | Symbravo |
| Adamas Pharmaceuticals, INC. | $11.62 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.